[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-cystic-fibrosis-bronchiectasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-cystic-fibrosis-bronchiectasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,45,69,95,118,143,179,205,226,248,282,304,324,351,376,399,419],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635034","phase-2-a-study-to-access-activity-and-safety-with-sar445399-compared-with-placebo-in-participants-aged-18-to-80-years-of-age-with-non-cystic-fibrosis-bronchiectasis-100635034",false,"NCT07547436","A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis","A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)","Inclusion Criteria:\n\n* Participants must be 18 to 80 years of age inclusive, at the time of signing the informed consent\n* Clinical history consistent with NCFB, such as chronic productive cough and\u002For recurrent respiratory infections\n* Documented evidence of at least 2 PEx defined as episodes requiring a physician-prescribed course of antibiotics (oral and\u002For IV) for ≥5 days for signs and symptoms of respiratory infection within the 12 months prior to the Screening Visit\n* Radiologic evidence of bronchiectasis, confirmed by a chest HRCT\n* A minimum MPS of 4 (out of maximum 18) on chest HRCT performed before Baseline Visit\n* Current sputum production with a documented history of chronic expectoration lasting ≥3 months within the previous 12 months\n* Participants must have a post-bronchodilator FEV1 ≥30% of predicted normal value\n\nExclusion Criteria:\n\n* A primary diagnosis of smoking-related COPD or asthma as determined by the Investigator. Participants with comorbid smoking-related COPD may be included if bronchiectasis is confirmed as their primary diagnosis and is the predominant cause of their respiratory symptoms\n* Diagnosis of ABPA or any of the allergic bronchopulmonary mycoses\n* Active NTM lung infection or incomplete NTM treatment course\n* Bronchiectasis due to any of the following: CF, CVID, AAT or PCD\n* History of significant hemoptysis (requiring medical intervention and\u002For requiring blood transfusion)\n* Current tobacco smokers\n* Known or suspected immunosuppression, including history of invasive opportunistic infections (eg., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the Investigator\n* Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease, including but not limited to connective tissue diseases (eg., systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, mixed connective tissue disease), rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, primary biliary cirrhosis, and psoriasis vulgaris\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","80 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).",[27],"Non-cystic Fibrosis Bronchiectasis",[29,30,31],"Non-Cystic Fibrosis Bronchiectasis","NCFB","Bronchiectasis","RECRUITING","2026-06-16",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":36},"2026-06-08",{"date":40,"type":21},"2028-08-07",{"name":42,"class":43},"Sanofi","INDUSTRY",4,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100611809","a-translational-study-for-phenotyping-and-endotyping-chinese-patients-with-ncfbe-100611809","NCT07245407","A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE","A Multi-center Longitudinal Observation Translational Study to Evaluate Phenotypes, Endotypes and Biomarkers in Chinese Patients With NCFBE","Inclusion Criteria:\n\nHealthy control cohort:\n\n· Age ≥30 years\n\nBronchiectasis cohort:\n\n* Capable of giving signed informed consent.\n* Participant must be ≥18 years of age, at the time of signing the ICF.\n* Able to perform acceptable lung function testing according to ATS\u002FERS 2019 acceptability criteria.\n* Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center, and use electronic devices (e.g. FENO and spirometry).\n* Documented physician-diagnosed bronchiectasis: with a clinical history consistent with bronchiectasis (chronic cough and daily sputum production etc.) and having performed chest HRCT indicating bronchiectasis.\n* Remaining clinically stable upon recruitment. Patients with exacerbations are allowed to be enrolled into the study at least 4 weeks after the end of exacerbations. If a patient experiencing exacerbation and directly enters the exacerbation visit, the patient is required to come to the study site for baseline visit (after confirming that all inclusion\u002Fexclusion criteria are met) within 4 weeks \u002F+ 3 days after the end of exacerbation\n\nExclusion Criteria:\n\nHealthy control cohort:\n\n* Any respiratory diagnosis (asthma, COPD, bronchiectasis, pulmonary fibrosis or any other chronic respiratory condition requiring regular treatment).\n* Inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, any other connective tissue disease.\n* Active malignancy excluding non-melanoma skin cancer.\n* Antibiotic treatment for an acute respiratory tract infection in the previous 4 weeks or current sinusitis.\n* Any contraindication to study procedures including bronchoscopy.\n* Current smoking or smoking in the preceding 3 months.\n* Treatment with anti-coagulants.\n\nBronchiectasis cohort:\n\n* Traction bronchiectasis associated with interstitial lung disease or other pulmonary disorders (e.g., pulmonary fibrosis and cystic fibrosis).\n* Primary diagnosis of another pulmonary condition, including COPD, asthma. Patients with a secondary diagnosis of these pulmonary diseases will be allowed to participate as long as bronchiectasis is considered by the investigator to be the primary diagnosis.\n* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:\n* Affect the safety of the participant throughout the study\n* Influence the findings of the study or the interpretation\n* Impede the participant's ability to complete the entire duration of study\n* The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation.\n* Active malignancy excluding non-melanoma skin cancer.\n* Participants is female who is pregnant or lactating or up to 6 weeks post-partum or 6 weeks cessation of breastfeeding.\n* The participant has an altered mental status at the time of informed consent.\n* History or current evidence of an upper or lower respiratory infection or symptoms(including common cold) within 2 weeks of baseline assessments\n* Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study center).\n* Terminal disease and\u002For organ failure or participants otherwise considered not appropriate for the study participation.",true,{"count":54,"type":21},320,"OBSERVATIONAL","Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic respiratory disease characterized by a clinical syndrome of chronic productive cough and recurrent respiratory infections in the presence of abnormal and permanent dilation of the bronchi. Recent epidemiological studies have clearly shown that the prevalence and incidence of NCFBE are quickly rising both in high- and low-income countries. With the increase of prevalence, bronchiectasis brings huge medical and economic burden to the society.\n\nIn this study, the investigator will perform biomarker assessments and multi-omics analysis on NCFBE patients and healthy participants in China to validate the link of disease pathways to pathophysiological features and uncover the molecular endotypes behind clinical phenotypesof Chinese patients with NCFBE.",[27],[59],"NCFBE","2026-06-15",{"date":33,"type":36},{"date":63,"type":36},"2025-10-27",{"date":65,"type":21},"2027-07-29",{"name":67,"class":43},"AstraZeneca",38,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100553529","long-term-evaluation-of-the-simeox-device-at-home-in-non-cystic-fibrosis-bronchiectasis-100553529","NCT06487273","Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis","Evaluation of the Impact of SIMEOX Airway Clearance Medical Device at Home, Combined With Remote Physiotherapy, on Quality of Life and Pulmonary Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis, Compared With Enhanced Standard of Care","Home-BRAC","Inclusion Criteria:\n\n* Male or female aged over 18 years\n* Predominant diagnosis of Non CF bronchiectasis disease, excluding cystic fibrosis, confirmed by computed tomography (CT).\n* Regular and chronic sputum production\n* Clinically stable at inclusion\n\n  * Defined by a delay of at least 4 weeks since the end of the last exacerbation according to the European consensus (Hill, European Respiratory Journal, 2017)\n  * No change in disease-modifying treatment for 4 weeks.\n* Having had at least two pulmonary exacerbations in the 12 months prior to inclusion and having required a change in specific treatment for these exacerbations.\n\nOr Having had at least one pulmonary exacerbation in the 12 months prior to inclusion requiring hospitalisation.\n\n* Considered by the investigator to be physically and psychologically able to use the device and carry out the procedures under study.\n* Patient covered by a social security system, when applicable in the concerned country\n\nExclusion Criteria:\n\n* Patients using one of the following motorised mechanical bronchial drainage devices at home at the time of inclusion:\n\n  * SIMEOX,\n  * an extra-thoracic high-frequency chest wall oscillation device (HFCWO) (The Vest,...)\n  * intrapulmonary percussion ventilation (IPV)\n* Patients who have been using a powered mechanical cough aid at home for less than a year at the time of inclusion:\n\n  * a mechanical in-exsufflator (MI E) such as the Cough Assist\n  * a pressure reducer such as the Alpha300\n* Cystic fibrosis\n* Predominant diagnosis of Chronic obstructive pulmonary disease (COPD) or asthma, traction bronchiectasis, bronchiectasis resulting from focal endobronchial lesion, sarcoidosis or active allergic bronchopulmonary aspergillosis.\n* Active smoking\n* Suspected (but undiagnosed) or unstabilised immune deficiency (at investigator's discretion)\n* In the case of long-term immunosuppressive treatment, risk of discontinuation of this treatment during the study.\n* Unstable cardiovascular pathologies (acute coronary syndrome, unstable angina pectoris, uncontrolled rhythm disorders, unstable heart failure)\n* Haemodynamic instability\n* Uncontrolled gastro-oesophageal reflux (persistence of symptoms despite treatment), at investigator's discretion.\n* Acute pneumothorax or increased susceptibility to pneumothorax\u002Fpneumomediastinum\n* Inability to cough vigorously and independently, at investigator's discretion\n* Had a significant episode of haemoptysis in the 6 weeks prior to inclusion, at the discretion of the investigator\n* Patient using an endotracheal tube, tracheostomy tube or daytime ventilation \\>16h with a mask\n* Patients with neuromuscular disease and respiratory muscle weakness, at the discretion of the investigator\n* Recent cardiothoracic surgery, including oesophageal surgery within 3 months of inclusion\n* Severe acute lung injury or barotrauma within 3 months of inclusion\n* Difficulty in evacuating secretions from the upper airways due to weakness of the respiratory muscles, or of the oropharyngeal or buccal musculature, at the discretion of the investigator\n* Risk of airway aspiration, e.g. from tube feeding or recent meals, at investigator's discretion\n* Inspiratory muscle weakness with inability to tolerate increased work of breathing, at investigator's discretion\n* Severe restrictive disease (Forced Vital Capacity \\\u003C 60% or Total Lung Capacity \\\u003C 60% with complete plethysmography)\n* Bullous emphysema\n* Participation in other interventional clinical study in the month prior to inclusion or during the study period\n* Patient unavailable or wishing to move to a region where the protocol is not present before the end of their participation\n* Vulnerable people:\n\n  * pregnant women (verified by a urine or blood human chorionic gonadotropin (HCG) test for all women wishing to participate in the protocol and of childbearing age, without contraception), breastfeeding mothers or women planning to become pregnant during the period of participation in the clinical investigation\n  * a person deprived of liberty by judicial or administrative decision\n  * a person subject to a legal protection measure",{"count":78,"type":21},622,[80],"NA","Bronchiectasis is a chronic lung disease of multiple aetiologies characterised by permanent dilatation of the calibre of a territory of the bronchial tree with impaired mucociliary clearance. This alteration causes mucus retention, leading to infections and chronic bronchial inflammation. Respiratory physiotherapy is one of the cornerstones of the management of these patients, in particular to facilitate bronchial drainage. In patients with abundant bronchial secretions, it is recommended that bronchial drainage sessions be carried out on a daily or more frequent basis, which represents a very substantial burden in terms of care. In addition, access to respiratory physiotherapy is not always easy for patients due to geographical or time constraints or the availability of professionals. Moreover, few professionals are trained in this specific care for chronic lung diseases.\n\nSIMEOX (Physio-Assist, France) is an innovative medical device (CE medical mark) for draining the bronchial tree. By means of a mouthpiece, this device generates a succession of very short intermittent negative air pressure pulses which disseminate a pneumatic vibratory signal in the patient's bronchial tree, modifying the rheological properties of the mucus, facilitating the mobilisation of secretions and assisting their transport towards the upper airways.\n\nA recent pilot study demonstrated that the use of SIMEOX independently by the patient at home for 3 months, combined with remote Physiotherapy (1 session\u002F2 weeks), provided a very satisfactory bronchial drainage solution for patients (satisfaction assessed at 9\u002F10 by visual analogue scale), with an improvement in their quality of life and very good compliance with the device (median of 4.7 sessions\u002Fweek).\n\nThis bronchial drainage strategy requires a long-term assessment.\n\nHypothesis: the use of SIMEOX independently by the patient at home could improve long-term quality of life and reduce the rate of pulmonary exacerbations in non-cystic fibrosis (non-CF) patients with bronchiectasis (bronchial dilatation) in comparison to Standard of Care (SoC).",[27],[84,85],"Non-CF Bronchiectasis","Bronchial clearance","2026-06-04",{"date":38,"type":36},{"date":89,"type":36},"2025-02-03",{"date":91,"type":21},"2027-12",{"name":93,"class":43},"Physio-Assist",57,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100562444","phase-1-a-study-to-test-the-safety-and-effects-of-inhaled-gdc-6988-in-participants-with-muco-obstructive-disease-100562444","NCT06603246","A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease","A Phase Ic, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-obstructive Disease","Inclusion Criteria:\n\n* Percent predicted FEV1 ≥ 40% by spirometry during screening\n* Ability to demonstrate correct use of the smart DPI at screening, in the investigator's judgment\n* On a stable treatment regimen for muco-obstructive diseases for ≥ 28 days prior to initiation of study treatment and willingness to remain on the stable treatment regimen through completion of study\n* Stable disease for ≥ 28 days prior to screening and through to initiation of study treatment\n\nAdditional Inclusion Criteria for Participants in Part B\n\n* Chronic sputum production of ≥1 teaspoon per day as reported in the sputum volume item\n* Ability to produce a sputum sample that is suitable for central laboratory determination of mucus percent solids and sialic acid concentration exploratory biomarker research, and biomarker assay development\n* Availability of a representative blood sample for exploratory biomarker research and biomarker assay development\n\nAdditional Inclusion Criteria for Participants With Non-cystic Fibrosis Bronchiectasis (NCFB) (Cohort 1, Cohort 2, and Cohort 3):\n\n\\- Diagnosis of bronchiectasis on the basis of prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung as assessed by the investigator\n\nAdditional Inclusion Criteria for Participants With Chronic Obstructive Pulmonary Disease (COPD) (Cohort 1, Cohort 2, and Cohort 4):\n\n* COPD defined as post-bronchodilator FEV1\u002FFVC ratio of \\\u003C0.7\n* Chronic bronchitis, with a definition including chronic cough and excessive sputum production for more than 3 months per year for at least 2 years prior to screening\n* Former smoker with a minimum of 10 pack-year history (e.g., 20 cigarettes\u002Fday for 10 years) or non-smoker with at least one documented COPD risk factor\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the timeframe in which contraception is required\n* Known significant bronchodilator response of \\>10% predicted change in FEV1 or FVC, in the investigator's judgment\n* Use of any prohibited medications\n* Acute respiratory infection within 28 days of screening\n* Significant hemoptysis greater than 60 milliliter (mL) within 3 months prior to screening\n* Known immunodeficiency that, in the investigator's judgment, is clinically significant and places the individual at a substantially elevated risk for opportunistic infections.\n* Known substance abuse, in the investigator's judgment, within 12 months prior to screening\n* Poor peripheral venous access\n* Receipt of blood products within 120 days prior to screening\n* Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgment, would preclude the individual's safe participation in and completion of the study or could affect the interpretation of the results\n* History of thoracic or metastatic malignancy within 5 years prior to screening\n* Known history of a clinically significant abnormal electrocardiogram (ECG), or presence of an abnormal ECG that is deemed clinically significant by the investigator\n* QT interval corrected through use of Fridericia's formula (QTcF) \\>450 milliseconds (ms) for males or \\>470 ms for females\n\nAdditional Exclusion Criteria for Participants in Part B -More than 2 chest CTs or other procedures known to expose the lungs to greater than 100 millisievert (mSv) within 12 months prior to screening\n\nAdditional Exclusion Criteria for Participants With NCFB (Cohort 1, Cohort 2, and Cohort 3)\n\n* Bronchiectasis primarily due to cystic fibrosis, primary ciliary dyskinesia, non-tuberculous mycobacterial infection, chronic aspiration, or predominantly traction bronchiectasis due to interstitial lung disease (ILD), in the investigator's judgment\n* Diagnosis of asthma, that in the investigator's judgment, is the primary driver of the individual's respiratory disease (e.g., primary asthma with incidental bronchiectasis findings)\n* NCFB exacerbation within 28 days prior to screening or that has not returned to baseline\n* Current smoker: Current smoking is defined as any use of inhaled tobacco products or inhaled marijuana within 3 months prior to screening, through use of cigarettes, cigars, electronic cigarettes, vaporizing devices, or pipes.\n\nAdditional Exclusion Criteria for Participants with NCFB in Cohort 3\n\n\\- Diagnosis of COPD that, in the investigator's judgment, is the primary driver of the individual's respiratory disease (e.g., primary COPD with incidental bronchiectasis findings)\n\nAdditional Exclusion Criteria for Participants With COPD (Cohort 1, Cohort 2, and Cohort 4):\n\n* COPD exacerbation within 28 days prior to screening or that has not returned to baseline\n* Asthma\u002FCOPD overlap syndrome",{"count":103,"type":21},128,[105],"PHASE1","This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.",[27,108],"Chronic Obstructive Pulmonary Disease","2026-06-02",{"date":86,"type":36},{"date":112,"type":36},"2024-11-18",{"date":114,"type":21},"2027-11-15",{"name":116,"class":43},"Genentech, Inc.",7,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100640002","phase-3-a-study-to-assess-the-safety-of-hsk31858-in-participants-with-non-cystic-fibrosis-bronchiectasis-100640002","NCT07616375","A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis","Phase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n* 1.Voluntarily sign the informed consent form; 2.Had previously participated in the HSK31858-301 study (having completed at least the randomization and having taken the first dose of medication); 3.If long-term treatment with bronchodilators (long-acting β-agonists and\u002For long-acting muscarinic antagonists) is required, the dose and regimen should remain stable throughout the study period.\n\n  4.Women must be post-menopausal, surgically sterile, or using highly effective contraception methods from Day 1 to at least 30 days after the last dose.\n\n  5\\. Males with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose.\n\nExclusion Criteria:\n\n* 1.In the HSK31858-301 study, there were cases of serious adverse events related to the investigational drug or subjects who were assessed by the investigators as requiring permanent discontinuation of the treatment.\n\n  2\\. Any other unstable clinical condition, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, psychiatric, or major physiological dysfunction, that the investigator considers to be (a) likely to affect patient safety throughout the study; (b) Influence the results of the study and its interpretation; (c) impeding the patient\\'s ability to complete the entire study.\n\n  3.Pregnancy and lactation. 4.The investigators judged that there were other conditions that were not suitable for participation in the study.",{"count":126,"type":21},669,[128],"PHASE3","This is a phase III, single-arm, open-label, multicenter study to assess the safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.",[27],[132],"non-cystic fibrosis bronchiectasis","2026-05-23",{"date":135,"type":36},"2026-06-01",{"date":137,"type":36},"2025-09-28",{"date":139,"type":21},"2029-04-03",{"name":141,"class":43},"Haisco Pharmaceutical Group Co., Ltd.",1,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":142},"100638185","phase-4-azithromycin-to-modify-bronchiectasis-exacerbation-risk-100638185","NCT07608328","Azithromycin to Modify Bronchiectasis Exacerbation Risk","AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis","AMBER","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).\n* Diagnosis supported by clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, respiratory follow-up services, or routine bronchiectasis care pathways at Assiut University Hospitals during the enrollment period.\n* Suitable for baseline disease-signature assessment.\n* Able to undergo protocol-defined clinical, functional, radiological, oxygenation, inflammatory, symptom, and safety assessment.\n* Able to complete planned 12-month follow-up.\n* Eligible for randomization after baseline safety evaluation.\n* Written informed consent obtained from the participant or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment, baseline assessment, or randomization.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Known hypersensitivity, contraindication, or serious intolerance to azithromycin or macrolide therapy.\n* Baseline cardiac findings judged by the investigator to make long-term azithromycin unsafe.\n* Requirement for long-term maintenance macrolide therapy at enrollment.\n* Current long-term maintenance macrolide use that cannot be safely discontinued before enrollment.\n* Inability to complete required baseline disease-signature assessment.\n* Inability or unwillingness to complete planned 12-month follow-up.\n* Refusal to participate.",{"count":152,"type":21},500,[154],"PHASE4","The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).\n\nThe trial evaluates whether azithromycin 250 mg orally once daily for 12 months, added to standard bronchiectasis care, reduces the occurrence of at least one bronchiectasis exacerbation during 12-month follow-up compared with matching placebo added to standard bronchiectasis care.\n\nParticipants will be randomized in a 1:1 allocation ratio to standard care plus matching placebo or standard care plus azithromycin. The primary analysis will follow the intention-to-treat (ITT) principle.\n\nThe AMBER trial is embedded within the Assiut University bronchiectasis translational research platform and is linked to the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework and the Bronchiectasis Phenotype Identification Model (BPIM). BASE and BPIM are not used for randomization stratification and will not modify the primary randomized comparison.\n\nThe locked Version 1.0 methodological disclosure document, protocol, and statistical analysis plan (SAP), primary sample-size source code, and endpoint-level sample-size support matrix are archived in Zenodo: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20178963.\n\nThe AMBER public preregistration is also available through the Open Science Framework (OSF) under Digital Object Identifier (DOI) 10.17605\u002FOSF.IO\u002FRE54V.",[27,157,31,158],"Bronchiectasis Adult","Bronchiectasis With Acute Exacerbation",[160,31,161,162,163,164,165,166,167,168],"Non-cystic fibrosis bronchiectasis (NCFB)","Bronchiectasis exacerbation","Exacerbation risk","azithromycin","macrolide therapy","double-blind placebo-controlled trial","randomized controlled trial (RCT)","12-month follow-up","Assiut University","NOT_YET_RECRUITING","2026-05-19",{"date":172,"type":36},"2026-05-27",{"date":174,"type":21},"2026-05-21",{"date":176,"type":21},"2027-06-30",{"name":168,"class":178},"OTHER",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":142},"100638565","base-bronchiectasis-severity-and-exacerbation-risk-study-100638565","NCT07599839","BASE: Bronchiectasis Severity and Exacerbation Risk Study","BASE: Bronchiectasis Assessment of Severity and Exacerbations for Baseline Severity Classification and One-Year Exacerbation Risk Prediction in Non-Cystic Fibrosis Bronchiectasis","BASE","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Clinically stable or routinely assessed patients with non-cystic fibrosis bronchiectasis (NCFB) eligible for baseline severity and risk assessment.\n* Patients attending outpatient clinic, inpatient ward, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for prospective baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned 12-month follow-up for bronchiectasis exacerbation and outcome assessment.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent 12-month follow-up.\n* Acute life-threatening illness preventing safe enrollment or baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete the required baseline or Bronchiectasis Assessment of Severity and Exacerbations (BASE) assessment according to the study protocol.\n* Inability or unwillingness to complete planned 12-month follow-up.\n* Refusal to participate.",{"count":188,"type":21},750,"Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by permanent bronchial dilatation, impaired mucus clearance, recurrent infection, airway inflammation, and repeated exacerbations. Existing bronchiectasis severity tools are clinically useful, but many depend on prior exacerbation history, hospitalization history, subjective symptom assessment, or culture-based microbiological classification.\n\nThis prospective observational cohort study aims to develop and validate the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework. BASE is designed to classify current bronchiectasis severity and predict 12-month exacerbation risk using objective baseline functional, radiological, oxygenation, and inflammatory variables. Detailed methodological specifications, including variable definitions, scoring architecture, endpoint hierarchy, development-validation governance, and analytical integrity rules, are archived in a restricted-access Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20143505\n\n.\n\nParticipants will receive routine clinical care, and no treatment or intervention will be assigned by the study protocol. Patients will be followed for 12 months to record bronchiectasis exacerbations, hospitalization, lung-function change, inflammatory marker change, and clinical outcomes. The Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework includes two linked baseline models: the BASE Severity model (BASE-S) for current bronchiectasis severity classification and the BASE Prognostic model (BASE-P) for prediction of 12-month exacerbation risk. Both models will be derived in the development cohort and applied unchanged to the validation cohort.",[31,27,158],[160,31,192,161,162,193,194,195,196],"Bronchiectasis severity","One-year exacerbation risk","Baseline risk prediction","Disease-signature model","Prospective observational cohort","2026-05-15",{"date":199,"type":36},"2026-05-20",{"date":201,"type":36},"2025-09-11",{"date":203,"type":21},"2027-02-01",{"name":168,"class":178},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":142},"100639767","bronchiectasis-phenotype-identification-model-100639767","NCT07599969","Bronchiectasis Phenotype Identification Model","BPIM: Bronchiectasis Phenotype Identification Model for Supervised Baseline Translation of Latent Class Trajectory Analysis-Derived Phenotypes in Non-Cystic Fibrosis Bronchiectasis","BPIM","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for baseline disease-signature assessment within the Bronchiectasis Phenotype Identification Model (BPIM) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned longitudinal follow-up required for latent class trajectory analysis (LCTA) and Bronchiectasis Phenotype Identification Model (BPIM) validation.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment or reliable baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete required baseline disease-signature assessment according to the Bronchiectasis Phenotype Identification Model (BPIM) protocol.\n* Inability or unwillingness to complete planned longitudinal follow-up.\n* Refusal to participate.",{"count":188,"type":21},"The Bronchiectasis Phenotype Identification Model (BPIM) is a prospective observational development-validation study within the Assiut University bronchiectasis translational research platform.\n\nThe study evaluates whether latent class trajectory analysis (LCTA)-derived bronchiectasis phenotype classes can be translated into a supervised baseline classifier for adults with non-cystic fibrosis bronchiectasis (NCFB).\n\nLatent class trajectory analysis (LCTA) will first identify trajectory-derived phenotype classes using prospectively collected longitudinal disease-signature data. The Bronchiectasis Phenotype Identification Model (BPIM) will then be trained to predict the accepted latent class trajectory analysis (LCTA)-derived phenotype class using the locked baseline disease-signature architecture.\n\nThis study is observational and non-interventional. No treatment, medication, intervention, exposure, or management strategy is assigned by the protocol. All participants receive routine clinical care according to institutional practice and treating physician judgment.\n\nThe locked methodological disclosure, protocol, and deterministic statistical analysis plan are archived in the version-specific Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20157926.",[31,27,158],[160,31,217,161,162,193,194,195,196,218,219,220],"Bronchiectasis Phenotype Identification Model (BPIM)","Development-validation study","Latent class trajectory analysis (LCTA)","supervised phenotype classifier",{"date":199,"type":36},{"date":201,"type":36},{"date":224,"type":21},"2026-12-01",{"name":168,"class":178},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":247},"100559055","phase-2-a-phase-ii-study-of-ensifentrine-in-non-cystic-fibrosis-bronchiectasis-100559055","NCT06559150","A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis","A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n* Males are eligible to participate if they agree to use contraception as described in the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication\n* Females are eligible to participate if they are not pregnant, not breastfeeding, and 1 of the following conditions apply:\n\n  1. Not a woman of childbearing potential (WOCBP) OR\n  2. A WOCBP who agrees to follow the contraceptive guidance from Screening throughout the study and for at least 30 days after the last dose of blinded study medication\n* Clinical history consistent with bronchiectasis (cough, chronic sputum production, and\u002For recurrent respiratory infections) confirmed by chest CT demonstrating bronchiectasis affecting 1 or more lobes. Confirmation may be based on prior chest CT within the prior 5 years; subjects whose past CT image records are not available will require chest CT scan during screening Notes: If a subject has no clinical history consistent with bronchiectasis, they may not be re-screened\n* Current sputum producer with a history of chronic expectoration and able to provide sputum sample spontaneously at the clinic during screening\n* ≥ 1 documented pulmonary exacerbation defined by an antimicrobial prescription (i.e., antibiotic or antiviral) by a physician for the signs and symptoms of respiratory infections in the past 12 months before screening\n* Capable of using the study nebulizer correctly\n* Ability to perform acceptable spirometry in accordance with American Thoracic Society and European Respiratory Society guidelines as assessed by the Investigator\n\nExclusion Criteria:\n\n* A diagnosis of COPD or a primary diagnosis of asthma, as judged by the investigator\n* Bronchiectasis due to cystic fibrosis, primary hypogammaglobulinemia common variable immunodeficiency, severe immunodeficiency, or requirement for treatment with intravenous immunoglobulin\n* Current smoker defined as by the Centers for Disease Control and Prevention (CDC)\n* Meets both of the following\n\n  1. Former cigarette smokers with a history of cigarette smoking ≥ 10 pack years at Screening \\[number of pack years = (number of cigarettes per day \u002F 20) × number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)\\]. Pipe and\u002For cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Screening AND\n  2. Evidence within 1 year prior to randomization of obstructed lung function as shown by forced expiratory volume in 1 second (FEV1)\u002Fforced vital capacity (FVC) ratio of \\\u003C 0.70\n* A diagnosis of primary ciliary dyskinesia (PCD) is not exclusionary. Subjects with a diagnosis of PCD are permitted to be enrolled, but the proportion of subjects with PCD enrolled in the study may be limited\n* Current treatment for nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis\n* Presence of acute exacerbation or acute infection that required acute treatment within 28 days of randomization\n* Use of the following prohibited medications within the designated time periods:\n\n  1. Chronic, systemic immunomodulatory agents for any chronic indication (including but not limited to the following: methotrexate, systemic corticosteroids, see adalimumab, azathioprine, dupilumab, cyclosporine, hydroxychloroquine, etc.) within 90 days prior to signing the ICF\n  2. CFTR modulators (e.g., ivacaftor, lumacaftor, tezacaftor) within 1 week prior to signing the ICF\n  3. Theophylline and oral PDE4 inhibitors (e.g., roflumilast, apremilast, crisaborole) within 48 hours prior to signing the ICF\n  4. Ohtuvayre at any time prior to signing the ICF\n* Initiated or altered therapy within 90 days prior to randomization with:\n\n  1. oral or inhaled antibiotics as chronic treatment (including macrolides)\n  2. Cyclic antibiotics: defined as prescribed regular cycles of on antibiotic treatment and off antibiotic treatment (for example, but not limited to, 28 days on an antibiotic and 28 days off an antibiotic). Note: Subjects on cyclic antibiotics must be actively taking antibiotics for at least 7 days prior to randomization through the day of randomization\n  3. Dipeptidyl peptidase 1 (DPP1) or cathepsin C (CatC) inhibitor (e.g., brensocatib)\n* Initiated or altered therapy with ICS within 4 weeks prior to randomization\n* Unable to withhold short-acting beta-agonists or short-acting muscarinic antagonists for ≥ 4 hours prior to spirometry\n* Significant hemoptysis (≥ 300 mL or requiring blood transfusion) within 6 weeks prior to randomization\n* Currently participating in or scheduled to participate in an intensive pulmonary rehabilitation program (a maintenance rehabilitation program is allowed if their schedule and procedure will be consistent for the duration of the study)\n* Current or chronic history of unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice, cirrhosis, or known hepatic or biliary abnormalities except for Gilbert syndrome or asymptomatic gallstones Note: Chronic stable hepatitis B and C is not exclusionary if the subject otherwise meets study entry criteria\n* History of or current malignancy of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\n* Alanine aminotransferase (ALT) ≥ 2 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≥ 2 × ULN, alkaline phosphatase and\u002For bilirubin \\> 1.5 × ULN (isolated bilirubin \\> 1.5 × ULN is acceptable only in subjects with a diagnosis of Gilbert's syndrome)\n* Participation in any other interventional, clinical studies (drugs or devices) within 30 days, or 5 half-lives, whichever is longer, prior to signing the ICF\n* Intolerance of or hypersensitivity to ensifentrine or any of its excipients\u002Fcomponents\n* Current or history of drug or alcohol abuse within the past 5 years\n* Significantly abnormal ECG finding",{"count":234,"type":21},284,[24],"This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).",[27],"2026-05-08",{"date":240,"type":36},"2026-05-13",{"date":242,"type":36},"2024-09-11",{"date":244,"type":21},"2027-09-24",{"name":246,"class":43},"Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",51,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":266,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":142},"100621866","digital-physiotherapy-for-pediatric-chronic-suppurative-lung-diseases-100621866","NCT07376187","Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases","Digital Physiotherapy Services in the Management of Pediatric Chronic Suppurative Lung Diseases: A Randomized Controlled Trial","Inclusion Criteria\n\n* children aged 6 to 12 years old\n* clinically stable with an absence of pulmonary exacerbation four weeks prior to the study's recruitment\n* adherence to attend regular medical follow-up from a pediatric pulmonologist every three months\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* Immunodeficiency or asthma as their primary condition\n* Clinical evidence of cardiovascular, neuromuscular, metastatic, or psychiatric comorbidities, and neuromuscular or musculoskeletal impairments that affect mobility and the ability to follow instructions\n* Medical history of lung transplant\n* Participation in other rehabilitation programs, or attendance at regular physiotherapy ACTs sessions (\\>10 sessions in a 3-month period)\n* Lack access to the internet (e.g., no smartphone, tablet, or laptop)\n* Inability to use technological devices","6 Years","12 Years",{"count":258,"type":21},32,[80],"This is a prospective, single-center, two-arm (1:1), assessor-blinded, randomized controlled clinical trial that will be conducted in collaboration with the outpatient clinic of the third Pediatric Pulmonology Unit, \"Attikon\" University Hospital of Athens in Greece. The aim of the study is to investigate the effects of applying digital physiotherapy services in the management of specific clinical outcomes in children with chronic suppurative lung diseases, other than cystic fibrosis. The research question is whether airway clearance techniques and exercise training that are performed remotely using digital health services (DHSs) can improve functional and exercise capacity, as well as compliance with ACTs, compared to usual care. The intervention program includes airway clearance techniques (ACTs), as well as aerobic and strengthening exercises that can be implemented easily in an online setting at home with minimal equipment. The duration of the program will be 12 weeks, and the prescribed weekly regimen will consist of 50-minute remote sessions: two synchronous, supervised sessions conducted via the Vsee platform, and a minimum of one asynchronous, unsupervised session. Children will be encouraged to maintain daily adherence to the exercise protocol.",[262,263,264,265],"Chronic Suppurative Lung Disease","Protracted Bacterial Bronchitis","Primary Ciliary Dyskinesia (PCD)","Non Cystic Fibrosis Bronchiectasis",[267,268,269,270,271,272],"chronic suppurative lung diseases","digital health services","pediatric","physiotherapy","remote","website","2026-01-28",{"date":275,"type":36},"2026-01-30",{"date":277,"type":21},"2026-05-01",{"date":279,"type":21},"2028-08-31",{"name":281,"class":178},"University of Thessaly",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":142},"100615196","phase-1-a-clinical-study-of-rss0343-in-healthy-subjects-100615196","NCT07289464","A Clinical Study of RSS0343 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RSS0343 Following Multiple Oral Doses in Healthy Subjects, as Well as Its Effects on the QT\u002FQTc Interval","Inclusion Criteria:\n\n1. Subjects who provided written informed consent after being fully informed of the trial's purpose, significance, and protocol requirements.\n2. Healthy individuals aged 18 to 55 years, inclusive. Males and females\n3. Body weight ≥ 50 kg for males and ≥ 45 kg for females. Body mass index (BMI) = weight (kg)\u002Fheight 2 (m²). BMI between 19 and 28 kg\u002Fm², inclusive.\n4. Fertile male and female subjects and their partners must agree to use highly effective contraception as stipulated in the protocol, from screening until 6 months (for females) or 3 months (for males) after the last dose. Additionally, fertile female subjects must have a negative serum pregnancy test at screening and prior to the first dose (baseline) and must not be lactating.\n\nExclusion Criteria:\n\n1. Subjects who smoked more than 5 cigarettes (or equivalent nicotine products) daily within 3 months prior to screening or intended to use tobacco products during the trial.\n2. Subjects with frequent alcohol consumption (\\>15 g\u002Fday for females or \\>25 g\u002Fday for males \\[5g of alcohol is equivalent to 150 mL of beer, 50 mL of wine or approximately 17 mL of low-alcohol liquor\\], on more than 2 occasions per week) within 6 months prior to screening, or were unable to abstain during the trial, or who tested positive on the alcohol breath test at baseline.\n3. Subjects with a history of, or current, drug abuse, or drug dependence (during consultation), or with a positive urine drug screening result.\n4. Subjects who had donated blood or experienced a total blood loss of ≥200 mL within 1 month, or ≥400 mL within 3 months prior to dosing, or who had received a blood transfusion within 8 weeks prior to dosing.\n5. Subjects with dysphagia; or a history of needle or blood phobia, poor venous access, or inability to tolerate venipuncture.\n6. Subjects deemed by the investigators to be unsuitable for the trial for any other reason.\n7. Subjects with any clinically significant abnormalities, as determined by the investigator, in physical examination, vital signs, laboratory tests (including hematology, urinalysis, blood biochemistry, coagulation), chest imaging, abdominal ultrasonography, or electrocardiogram.\n8. Subjects who tested positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody.\n9. Subjects with a known or suspected allergy to the investigational drug or its excipients, or a history of severe allergic reactions (e.g., to drugs, food, toxins).\n10. Subjects with any active autoimmune disease or immunodeficiency at screening.\n11. Subjects with any history of severe clinical disease, or any condition that, in the investigator's judgment, could compromise trial outcomes, affect drug absorption, distribution, metabolism, or excretion (pharmacokinetics), or pose an undue risk to the subject. This includes, but is not limited to, significant disorders of the circulatory, endocrine, nervous, digestive, urinary, hematological, immune, psychiatric, or metabolic systems.\n12. Subjects who had undergone any surgery within 3 months prior to screening, had not fully recovered as determined by the investigator, or planned to undergo surgery during the trial or within 1 month after its completion.","55 Years",{"count":291,"type":21},48,[105],"This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT\u002FQTc interval.",[27],"2026-01-13",{"date":297,"type":36},"2026-01-14",{"date":299,"type":36},"2026-01-04",{"date":301,"type":21},"2026-09",{"name":303,"class":43},"Reistone Biopharma Company Limited",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":311,"maxAge":18,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":142},"100505395","breathing-training-and-exercise-capacity-in-non-cfb-100505395","NCT05860803","Breathing Training and Exercise Capacity in Non-CFB","Home-based, Digitally Delivered Breathing Training in People With Non-cystic Fibrosis Bronchiectasis: A Randomized Control Trial","Inclusion Criteria:\n\n* Mayo Clinic patient with confirmed diagnosis of Non-Cystic Fibrosis Bronchiectasis (non-CFB): Non-CFB as confirmed by clinical history, including cough, shortness of breath, exertional dyspnea, pulmonary function tests, and high-resolution computed tomography. Patients will be considered clinically stable if there is no evidence of an exacerbation or change(s) in medical therapy in the previous three weeks.\n* Able and willing to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of significant coexisting disease, neurological conditions, and\u002For orthopedic complications that affect ability to undertake exercise.\n* Presence of advanced heart failure.\n* Current use of antibiotics.\n* Acute exacerbation(s) within 3-weeks prior to study commencement.\n* Participation within a pulmonary rehabilitation program within 6-months prior to study commencement.","21 Years",{"count":313,"type":21},50,[80],"The purpose of this research is to investigate whether a home-based and health coach supported specific breathing and respiratory muscle training program improves the ability to exercise, the function of the lungs and breathing muscles, and general clinical status in people with non-cystic fibrosis bronchiectasis (non-CFB).",[27],{"date":318,"type":36},"2026-01-06",{"date":320,"type":36},"2024-01-15",{"date":224,"type":21},{"name":323,"class":178},"Mayo Clinic",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100596653","phase-2-dose-range-finding-efficacy-and-safety-study-of-nebulized-csl787-in-adults-with-non-cystic-fibrosis-bronchiectasis-ncfb-100596653","NCT07048262","Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)","A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n* Adult between the ages of 18 to 85 years\n* Primary diagnosis of NCFB confirmed by chest computed tomography (CT) scan, where bronchiectasis has been documented by a radiologist. Diagnosis in the medical records based on historical scans is acceptable if the chest CT scan confirming the participant's NCFB diagnosis was performed within 12 months before enrollment. Participants for whom no chest CT scan results are available within the previous 12 months will undergo a chest CT scan during the Screening Period\n* Exacerbation history within the previous 1 year defined as either 1 of the following:\n* \\>= 2 documented exacerbations requiring oral and\u002For intravenous (IV) antibiotic therapy to treat a pulmonary infection.\n\nOR\n\n* 1 documented exacerbation requiring oral and\u002For IV antibiotic therapy to treat a pulmonary infection and a St. George's Respiratory Questionnaire (SGRQ) Symptoms score of \\> 40 at Screening.\n* Note: Other medications to treat NCFB such as: oral macrolides, or dipeptidyl peptidase-1 (DPP-1) inhibitors are allowed, provided \\>= 1 historical exacerbation occurred while on the medication for \\>= 3 months at a stable dose.\n* Postbronchodilator percentage of the predicted normal forced expiratory volume in 1 second of expiration \\[FEV1% predicted\\] \\> 35% and forced expiratory volume in 1 second (FEV1) \\>= 1 liter (L) obtained in accordance with American Thoracic Society (ATS) \u002F European Respiratory Society (ERS) standards for spirometry during Screening and at Baseline.\n\nExclusion Criteria:\n\n* History of bronchospasm in response to inhaled therapies including inhaled antibiotics\n* Known or suspected hypersensitivity, or other severe reactions, to the investigational product (IP), to any excipients of the IP, or to other immunoglobulin.\n* Primary diagnosis of other pulmonary disorders, including chronic obstructive pulmonary disease (COPD) asthma or, diffuse panbronchiolitis (DPB), as determined by the investigator.\n* Pulmonary exacerbation requiring antibiotic therapy within the 4 weeks before Baseline.","85 Years",{"count":333,"type":21},450,[24],"This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (immunoglobulin G \\[IgG\\] inhalation solution) compared with placebo over a period of 6 to 12 months independent of the occurrence of pulmonary exacerbations.\n\nThe primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the TTF exacerbation.",[27],[338,339,340],"Chronic respiratory disease","Inflammation","Chronic bacterial infection","2025-11-06",{"date":343,"type":36},"2025-11-10",{"date":345,"type":36},"2025-09-03",{"date":347,"type":21},"2028-03-28",{"name":349,"class":43},"CSL Behring",13,{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":142},"100534743","phase-4-hypertonic-saline-in-ncfb-100534743","NCT06242795","Hypertonic Saline in NCFB","Effect of Hypertonic Saline on Mucociliary Clearance in Non-CF Bronchiectasis","Inclusion Criteria:\n\n* Adults \\>18 years of age able to provide informed consent\n* Diagnosis of bronchiectasis confirmed on prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung\n* Forced expiratory volume in one second (FEV1) % predicted \\> 40%, inclusive\n* History of prior bronchiectasis exacerbations (requiring antibiotics)\n* Chronic cough\n\nExclusion Criteria\n\n* Diagnosis of cystic fibrosis (CF), primary ciliary dyskinesia (PCD), chronic aspiration, or predominantly traction bronchiectasis due to interstitial lung disease (ILD)\n* Unable or unwilling to undergo HS washout period of 2 weeks preceding first baseline MCC scan\n* Concomitant inhaled acetylcysteine or dornase alfa use\n* Recent pulmonary exacerbation in preceding 4 weeks\n* History of intolerance to HS (bronchospasm, hemoptysis)\n* History of significant hemoptysis (\\>60 ml) within the preceding 3 months\n* Chronic supplemental oxygen use at rest\n* Severe asthma, as reflected by need for chronic oral corticosteroids (\\>10mg\u002Fday), asthma biologic therapies, hospitalization for status asthmaticus within the past year, or bronchiectasis felt to have resulted from chronic asthma\n* Significant bronchodilator response (\\>15% increase in FEV1 or forced vital capacity \\[FVC\\]) on pre-post spirometry testing during screening visit\n* Failed HS tolerability test (HSTT) at screening, as indicated by:\n* Intolerable symptoms after HS administration\n* Decline in FEV1 % predicted by \\>20% when measured 15 min after HS administration\n* Decline in FEV1 % predicted between 10-20% when measured at 15 min that does not recover to within 10% of baseline without intervention 1 hour post HS test dose\n* Smoking\u002Fvaping, any substance within the past year, or \\>10 pack-years of cigarette use over their lifetime\n* More than 2 chest CTs in the past year or a combination of procedures believed to have exposed the lungs to \\>150 millisieverts (mSv)\n* Current\u002Frecent participation in other interventional studies for NCFB, allowing for appropriate wash-out time\n* Pregnancy",{"count":359,"type":21},20,[154],"The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a person's lungs can clear inhaled particles will be assessed at baseline, and after acute (single dose) HS treatment, as well as after two weeks of treatment with HS.\n\nThe study has two main questions:\n\n1. Evaluate the repeatability MCC measures in people with non-CF bronchiectasis\n2. Compare MCC at baseline (before treatment with HS), after a single dose of HS (acute effect of HS), and after two weeks of treatment with HS twice a day (sustained effect of HS).\n\nParticipants will participate in up to 5 study visits if completing both Aim 1 and Aim 2: 1 screening\u002Fenrollment visit, 2 baseline visits (1 baseline visit if only participating in Aim 2), 1 visit during which first dose of HS would be administered and assessed, and 1 visit after 2 weeks of treatment with HS.",[31,27],[364,365,366],"airway clearance","mucociliary clearance","hypertonic saline","2025-08-11",{"date":369,"type":36},"2025-08-13",{"date":371,"type":36},"2024-10-23",{"date":373,"type":21},"2026-06",{"name":375,"class":178},"University of North Carolina, Chapel Hill",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":331,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":142},"100591489","phase-2-a-multicenter-randomized-double-blind-placebo-controlled-parallel-group-phase-2-clinical-trial-to-evaluate-the-efficacy-and-safety-of-xh-s004-tablets-in-patients-with-non-cystic-fibrosis-bronchiectasis-100591489","NCT06981091","A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n1. Understand the procedures and methods of this trial and sign a written informed consent form;\n2. Male or female paticipants aged 18-85 years (inclusive) ;\n3. Chest HRCT shows bronchiectasis affecting one or more lobes, and the condition is clinically diagnosed as non-cystic fibrosis bronchiectasis (clinical manifestations include chronic cough, significant productive cough, and\u002For intermittent hemoptysis, with or without varying degrees of polypnoea and other symptoms);\n4. Based on medical history and the determination of the investigator , participants have at least 2 documented pulmonary exacerbations in the past 12 months before Screening;\n5. Are current sputum producers with a history of chronic expectoration and able to provide a spontaneous sputum sample at screening visit (as described by the patient) ;\n6. The body mass index (BMI) is ≥18 kg\u002Fm2 at screening;\n7. Participants must ensure and agree that from 28 days prior to signing the informed consent form to 28 days after the final administration, women of childbearing potential, male participants, and their partners will use effective contraception methods other than oral drugs (e.g., condoms or intra-uterine contraceptive devices) and will not donate sperm or eggs during this period\n\nExclusion Criteria:\n\n1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma\n2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency\n3. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis\n4. Have any acute infections, (including respiratory infections)\n5. Patients who have previously received therapy with DPP1 inhibitors of the same class",{"count":383,"type":21},231,[24],"The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.",[29],[31,388,389],"Active neutrophil elastase","Fibrosis","2025-05-12",{"date":392,"type":36},"2025-05-20",{"date":394,"type":21},"2025-05-16",{"date":396,"type":21},"2027-04-28",{"name":398,"class":43},"S-INFINITY Pharmaceuticals Co., Ltd",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":418},"100566885","phase-3-a-study-to-assess-the-efficacy-and-safety-of-hsk31858-in-participants-with-non-cystic-fibrosis-bronchiectasis-100566885","NCT06660992","A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis","Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n* 1\\. Age ≥18 years and BMI≥18.0 kg\u002Fm\\^2 at the time of signing the ICF. 2. Chest HRCT showed bronchiectasis affecting one or more lobes and was confirmed by a clinician as NCFBE(clinically characterized by chronic cough, expectoration and\u002For intermittent hemoptysis, with or without shortness of breath and respiratory failure). HRCT was considered effective if the patient had received HRCT in the same hospital within 12 months and screening HRCT is not necessary.\n\n  3\\. Have at least 2 pulmonary exacerbations in the past 12 months before Screening.\n\n  4\\. If long-term treatment with bronchodilators (long-acting β-agonists and\u002For long-acting muscarinic antagonists) is required, the dose and regimen should remain stable for at least 3 months before the screening visit and throughout the study period.\n\n  5\\. The estimated survival time ≥ 12 months. 6. Women must be post-menopausal, surgically sterile, or using highly effective contraception methods from Day 1 to at least 30 days after the last dose.\n\n  7\\. Males with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose.\n\n  8\\. Give their signed study informed consent to participate.\n\nExclusion Criteria:\n\n* 1\\. Have a primary diagnosis of COPD or asthma as judged by the Investigator. 2. A history of malignancy (excluding cured basal cell carcinoma of the skin, carcinoma in situ, and papillary carcinoma of the thyroid gland. The patients who had survived lung cancer surgery for at least 5 years without antitumor therapy can enroll in the study ) within 5 years prior to screening or a history of antitumor therapy.\n\n  3\\. Have bronchiectasis due to CF (HRCT showed that the above lung diseases became predominant) as judged by the Investigator.\n\n  4\\. Currently being treated Non-tuberculous Mycobacterial (NTM) pulmonary infections, allergic bronchopulmonary aspergillosis, or tuberculosis (TB), or active and currently symptomatic infections caused by COVID-19, or have the history of bronchopulmonary aspergillosis.\n\n  5\\. Patients with severe pulmonary fibrosis such as lung destruction, pneumonectomy surgery history, and pneumoconiosis, as well as previous or existing decompensated stage of pulmonary heart disease.\n\n  6\\. Patients who had experienced any degree of acute exacerbation of bronchiectasis or were developing an acute exacerbation of bronchiectasis before 4 weeks of screening.\n\n  7\\. Patients who had hemoptysis and required medical intervention within 4 weeks prior to screening(except for coughing up minorbloody streaks).\n\n  8\\. Patients previously treated with HSK31858 or other DPP1 inhibitor products. 9. Subjects with uncontrolled hypertension (SBP ≥180 mmHg at rest and\u002For DBP ≥110 mmHg). 10. Subjects with uncontrolled type 1 or type 2 diabetes (fasting plasma glucose \\>7.0 mmol\u002FL).\n\n  11\\. Subjects with a history of liver disease or current treatment for liver disease during the screening period, including but not limited to acute or chronic hepatitis, cirrhosis or liver failure (except for mild to moderate non-alcoholic fatty liver disease).\n\n  12\\. Active hepatitis B virus infection (hepatitis B surface antigen positive with HBV-DNA load above the lower limit of detection), active hepatitis C virus infection (HCV antibody positive with HCV-RNA load above the lower limit of detection), or known HIV infection or syphilis infection.\n\n  13\\. Any other unstable clinical condition, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, psychiatric, or major physiological dysfunction, that the investigator considers to be (a) likely to affect patient safety throughout the study; (b) Influence the results of the study and its interpretation; (c) impeding the patient\\'s ability to complete the entire study.\n\n  14\\. Laboratory tests during the screening period meet the following conditions:\n  1. AST\\>2.0×ULN or ALT\\>2.0×ULN or TBIL\\>1.5×ULN\n  2. eGFR\\<60ml\u002Fmin\u002F1.73m2\n  3. Hb\\\u003C90 g\u002FL\n  4. WBC \\\u003C3×109 \u002FL\n  5. PLT \\\u003C70×109 \u002FL\n  6. INR\\>1.5ULN，PT\\>ULN+3s, or APTT\\>ULN+10s. 15. Had participated in a clinical trial of any other drug or medical device in the 3 months prior to the screening (a drug or medical device treated with a clinical trial) or the subject had not been more than 5 half-lives from the last clinical trial of the drug at the time of screening.\n\n     16\\. Medications that may cause hyperkeratosis (e.g., tumor necrosis factor-α antagonists) within 4 weeks prior to screening.\n\n     17\\. Patients who have used a strong inducer or suppressor of CYP3A within 14 days or 5 half-lives of the first investigational drug (whichever is longer).\n\n     18\\. Patients who had smoked an average of 10 cigarettes or more per day in the previous 1 year were screened.\n\n     19\\. Pregnancy and lactation. 20. The subjects were unable to complete the questionnaires due to their limited educational level, or the subjects and their families failed to fill in the subjects\\' log cards.\n\n     21\\. Had received live attenuated vaccine within 30 days before randomization. 22. The investigators judged that there were other conditions that were not suitable for participation in the study.",{"count":126,"type":21},[128],"This is a phase III, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.",[27],"2024-10-24",{"date":412,"type":36},"2024-10-28",{"date":414,"type":36},"2024-09-30",{"date":416,"type":21},"2027-01-27",{"name":141,"class":43},2,{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":17,"enrollmentInfo":426,"targetDuration":428,"studyType":55,"phases":4,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":4},"100543213","procalcitonin-as-a-marker-of-severity-of-non-cystic-fibrosis-bronchiectasis-in-children-100543213","NCT06352944","Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children","Bronchoscopic Derived Bronchoalveolar Lavage Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children","Inclusion Criteria:\n\n1. Children of both sex\n2. Children aged from 6-17 years old.\n3. Documented diagnosis of non-CF bronchiectasis by confirmed bronchiectasis findings using high-resolution computed tomographic (HRCT) lung scanning, and clinical symptoms consistent with bronchiectasis with a negative sweat test\n\nExclusion Criteria:\n\n1. Age less than 6 years or more than 17 years.\n2. Children Diagnosed with cystic fibrosis bronchiectasis with confirmed positive sweat chloride test(6).\n3. If there was a history of a recent exacerbation during the previous month preceding the study.",{"count":427,"type":21},30,"1 Year","The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity )",[27],"2024-04-15",{"date":433,"type":36},"2024-04-17",{"date":435,"type":21},"2024-07",{"date":437,"type":21},"2026-07",{"name":168,"class":178}]